Sonnet BioTherapeutics Announces Tragic Loss of Founder and CEO, Pankaj Mohan, and Leadership Transition
Princeton, N.J., April 01, 2025 – Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (“Sonnet” or the “Company”), a clinical-stage biotech company specializing in the development of immunotherapeutic drugs for the tumor microenvironment (TME), shares the heartfelt sadness of the loss of its Founder and Chief Executive Officer, Pankaj Mohan, Ph.D. The Company made this announcement with a deep sense of sorrow.
Background on Pankaj Mohan
Dr. Mohan was an influential figure in the biotech industry, having dedicated his career to advancing cancer research and treatments. He founded Sonnet BioTherapeutics in 2015 with a vision to revolutionize cancer treatment through targeted immunotherapies. Under his leadership, Sonnet grew from a small startup to a promising clinical-stage company.
Leadership Transition
In response to this unfortunate event, Sonnet’s Board of Directors has appointed current board member Raghu Rao as Interim Chief Executive Officer of the Company. Additionally, the Board has promoted Stephen McAndrew, Ph.D., the Company’s current Chief Business Officer, to the position of President and Chief Business Officer.
Impact on Sonnet
The Board of Directors intends to initiate a search for a permanent CEO to lead Sonnet through its next stages of growth. Dr. Mohan’s passing is a significant loss for the organization, but the team remains committed to continuing the development of their pipeline of immunotherapeutic drugs. The Company’s operations will continue as usual.
Personal Impact
As an individual investor, this news may not have an immediate impact on your portfolio. However, if you have invested in Sonnet BioTherapeutics, it is essential to monitor the company’s progress and any updates on the CEO search. The loss of a visionary leader like Dr. Mohan could potentially impact the Company’s morale and development strategy.
Global Impact
The biotech industry as a whole may feel the ripple effects of Dr. Mohan’s passing, as he was a respected leader and innovator in the field of cancer research and immunotherapies. His contributions to Sonnet and the industry will be missed, and his legacy will continue to inspire future generations of researchers and entrepreneurs.
- Sonnet BioTherapeutics announces the passing of Founder and CEO, Pankaj Mohan, Ph.D.
- Raghu Rao named Interim CEO, and Stephen McAndrew promoted to President and CBO.
- Board of Directors to launch a search for a permanent CEO.
- Impact on investors: monitor Sonnet’s progress and updates on the CEO search.
- Impact on the biotech industry: loss of a respected leader and innovator in cancer research and immunotherapies.
Conclusion
Sonnet BioTherapeutics, a clinical-stage biotech company specializing in the development of immunotherapeutic drugs for the tumor microenvironment, announced the tragic passing of its Founder and CEO, Pankaj Mohan, Ph.D. The Board of Directors has appointed Raghu Rao as Interim CEO and promoted Stephen McAndrew to President and CBO. The Company intends to launch a search for a permanent CEO. This loss will have both personal and global implications, and it is crucial for investors and industry observers to stay informed on Sonnet’s progress.
